The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Open accessAbstract
Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage–specific risk of all‐cause and liver‐related mortality in NAFLD. Through a systematic review and meta‐analysis, we identified five adult NAFLD cohort studies reporting fibrosis stage–specific mortality (0‐4). Using fibrosis stage 0 as a reference population, fibrosis stage–specific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all‐cause and liver‐related mortality were estimated. The study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. Included were 1,495 NAFLD patients with 17,452 patient years of follow‐up. Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all‐cause mortality, and this risk increased with increases in the stage of fibrosis: stage 1, MRR = 1.58 (95% CI 1.19‐2.11); stage 2, MRR = 2.52 (95% CI 1.85‐3.42); stage 3, MRR = 3.48 (95% CI 2.51‐4.83); and stage 4, MRR = 6.40 (95% CI 4.11‐9.95). The results were more pronounced as the risk of liver‐related mortality increased exponentially with each increase in the stage of fibrosis: stage 1, MRR = 1.41 (95% CI 0.17‐11.95); stage 2, MRR = 9.57 (95% CI 1.67‐54.93); stage 3, MRR = 16.69 (95% CI 2.92‐95.36); and stage 4, MRR = 42.30 (95% CI 3.51‐510.34). Limitations of the study include an inability to adjust for comorbid conditions or demographics known to impact fibrosis progression in NAFLD and the inclusion of patients with simple steatosis and nonalcoholic steatohepatitis without fibrosis in the reference comparison group. Conclusion: The risk of liver‐related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (H epatology 2017;65:1557‐1565).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of liver fibrosis remains the most robust histological predictor of liver-related morbidity and mortality in patients with MASLD (Dulai et al. 2017).”
From The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion (2026) · cites this paper as Dulai et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“prognosis is mostly influenced by the grade of fibrosis rather than presence/absence of NASH [9, 10].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“once a diagnosis of NASH and/or advanced fibrosis (i.e. fibrosis stage 3 or cirrhosis) and/or portal hypertension is confirmed patients are at an increased risk for liver‐related complications (i.e. hepatic decompensation and hepatocellular carcinoma) and liver‐related mortality [9, 10, 25].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [259]
In the citing paper
“Among these features, the extent of fibrosis is the strongest predictor of patient mortality, and is therefore the focus of drug development efforts (13-16).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [16]
In the citing paper
“Such clinical observations, coupled with the knowledge that fibrosis is the most significant predictor of patient mortality in MASH, focus renewed attention on mechanisms of both spontaneous and pharmacologic-induced fibrosis regression (13-16), as more research is needed to develop clinical interventions that halt progression or reverse the disease.”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Self-citationNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,004
Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis, V., & Papatheodoridis, G. (2023) · European journal of internal medicine · doi:10.1016/j.ejim.2023.11.005 · Cited by 222
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Kaya, E., & Yilmaz, Y. N. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00178 · Cited by 241
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Self-citationNg, C. H., Lim, W. H., Lim, G. E. H., Tan, D. J. H., Syn, N. L. X., Muthiah, M. D., Huang, D. Q., & Loomba, R. S. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.014 · Cited by 232
Self-citationDifferential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Nguyen, V. H., Le, M. H., Cheung, R. C., & Nguyen, M. H. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.029 · Cited by 217
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Lim, S. K., Kim, J., & Targher, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.04.008 · Cited by 224
Imaging biomarkers of NAFLD, NASH, and fibrosis
Ajmera, V. H., & Loomba, R. S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101167 · Cited by 214
Self-citationTillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Henry, L. L., Paik, J. M., & Younossi, Z. M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17158 · Cited by 217
Self-citationYounossi, Z. M., Tampi, R. P., Priyadarshini, M., Nader, F., Younossi, I. M., & Racila, A. (2018) · Hepatology · doi:10.1002/hep.30254 · Cited by 212
Self-citationIntestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q. ‐., & Ciaula, A. D. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 219
Choi, H. S. J., Brouwer, W. P., Zanjir, W. M. R., de Man, R. A., Feld, J. J., Hansen, B. E., Janssen, H. L. A., & Patel, K. (2020) · Hepatology · doi:10.1002/hep.30857 · Cited by 211
Lindén, D., Ahnmark, A., Pingitore, P., Ciociola, E., Ahlstedt, I., Andréasson, A., Sasidharan, K., Madeyski-Bengtson, K., Zurek, M., Mancina, R. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.013 · Cited by 211
Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.024 · Cited by 208
Self-citationCaussy, C., Hsu, C., Lo, M., Liu, A., Bettencourt, R., Ajmera, V. H., Bassirian, S., Hooker, J., Sy, E., Richards, L., et al. (2018) · Hepatology · doi:10.1002/hep.29892 · Cited by 205
Self-citationYounes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322564 · Cited by 205
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Wang, X., Cai, B., Yang, X., Sonubi, O. O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U. B., Sandhu, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.010 · Cited by 204
A researcher’s guide to preclinical mouse NASH models
Gallage, S., Avila, J. E. B., Ramadori, P., Focaccia, E., Rahbari, M., Ali, A., Malek, N. P., Anstee, Q. M., & Heikenwälder, M. F. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00700-y · Cited by 212
Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease
Mato, J. M., Alonso, C., Noureddin, M., & Lu, S. C.-L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.3009 · Cited by 205
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12511 · Cited by 197
Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
Fan, J., Wei, L., & Zhuang, H. (2018) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12685 · Cited by 198
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Self-citationHarrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1657 · Cited by 197
Nonalcoholic fatty liver disease: Evolving paradigms
Lonardo, A., Nascimbeni, F., Maurantonio, M., Marrazzo, A., Rinaldi, L., & Adinolfi, L. E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6571 · Cited by 204
Xu, F., Guo, M., Huang, W., Feng, L., Zhu, J., Luo, K., Gao, J., Zheng, B., Kong, L.-D., Pang, T., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101634 · Cited by 196
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
Self-citationHoang, S. A., Oseini, A. M., Feaver, R. E., Cole, B. K., Asgharpour, A., Vincent, R. J., Siddiqui, M. S., Lawson, M. J., Day, N., Taylor, J. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48746-5 · Cited by 195
Current therapies and new developments in NASH
Dufour, J., Anstee, Q. M., Bugianesi, E., Harrison, S. A., Loomba, R. S., Paradis, V., Tilg, H., Wong, V. W., & Zelber‐Sagi, S. (2022) · Gut · doi:10.1136/gutjnl-2021-326874 · Cited by 192
Self-citationHuang, D. Q., Wilson, L. A., Behling, C., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Amangurbanova, M., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.025 · Cited by 190
Self-citationLoomba, R. S., Wong, R. J., Fraysse, J., Shreay, S., Li, S., Harrison, S. A., & Gordon, S. C. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15679 · Cited by 187
Self-citationPathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
Bansal, S., & Bansal, M. B. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17930 · Cited by 211
Pathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 188
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F. M., & Mehal, W. Z. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 206
Fu, L., Yao, T. S., Chen, Q., Mo, X., Hu, Y., & Guo, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16881 · Cited by 178
Kim, D., Vazquez‐Montesino, L. M., Li, A. A., Cholankeril, G., & Ahmed, A. (2020) · Hepatology · doi:10.1002/hep.31158 · Cited by 177
Simon, T. G., Roelstraete, B., Sharma, R., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Hepatology · doi:10.1002/hep.31845 · Cited by 176
Liu, Y., Zhong, G.-C., Tan, H.-Y., Hao, F.-B., & Hu, J.-J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47687-3 · Cited by 176
Modelling NAFLD disease burden in four Asian regions—2019‐2030
Estes, C., Chan, H. L., Chien, R., Chuang, W., Fung, J., Goh, G. B., Hu, T. H., Huang, J., Jang, B. K., Jun, D. W., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15673 · Cited by 181
Self-citationNonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R. S., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 187
Self-citationNoureddin, M., Charlton, M., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R. S., Sanyal, A. J., & Rinella, M. E. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.003 · Cited by 170
Self-citationNonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Lee, Y., Cho, Y., Lee, B., Park, C., Lee, D. H., Soo, B., & Rhee, E. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0011 · Cited by 169
Ajmera, V. H., Park, C. C., Caussy, C., Singh, S., Hernandez, C., Bettencourt, R., Hooker, J. C., Sy, E. Z., Behling, C. A., Xu, R., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.014 · Cited by 167
Self-citationNon-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
Kumar, R., Priyadarshi, R., & Anand, U. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00051 · Cited by 176
Sterling, R. K., Patel, K., Duarte‐Rojo, A., Asrani, S. K., Alsawas, M., Dranoff, J. A., Fiel, M. I., Murad, M. H., Leung, D. H., Levine, D., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000845 · Cited by 188
Chang, Y., Ryu, S., Sung, K., Cho, Y. K., Sung, E., Kim, H., Jung, H. S., Yun, K. E., Ahn, J., Shin, H. C., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-317666 · Cited by 165
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164
Self-citationSerotonin signals through a gut-liver axis to regulate hepatic steatosis
Choi, W., Namkung, J., Hwang, I., Kim, H., Lim, A., Lee, H. W., Lee, H. W., Han, K., Park, S., Jeong, J.-S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07287-7 · Cited by 166
Jung, J., Loomba, R., Imajo, K., Madamba, E. V., Gandhi, S., Bettencourt, R., Singh, S., Hernandez, C., Valasek, M. A., Behling, C. A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322976 · Cited by 168
Self-citationThe Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chavez, C. P., Cusi, K. J., & Kadiyala, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 165
Tincopa, M. A., & Loomba, R. S. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00066-3 · Cited by 163
Self-citationChang, Y., Cho, Y. K., Kim, Y., Sung, E., Ahn, J., Jung, H., Yun, K. E., Shin, H. C., & Ryu, S. (2018) · Hepatology · doi:10.1002/hep.30170 · Cited by 162
Scorletti, E., & Byrne, C. D. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.03.001 · Cited by 168
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Boursier, J., Guillaume, M., Leroy, V., Irlès, M., Roux, M., Lannes, A., Foucher, J., Zuberbuhler, F., Delabaudière, C., Barthelon, J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.020 · Cited by 157
Nonalcoholic Fatty Liver Disease in Children
Mann, J. P., Valenti, L. V. C., Scorletti, E., Byrne, C. D., & Nobili, V. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1627456 · Cited by 169
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Sanyal, A. J., Neuschwander‐Tetri, B. A., & for the Nonalcoholic Steatohepatitis Clinical Research Network (2019) · Hepatology · doi:10.1002/hep.30418 · Cited by 154
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
NAFLD: Reporting Histologic Findings in Clinical Practice
Brunt, E. M., Kleiner, D. E., Carpenter, D. H., Rinella, M. E., Harrison, S. A., Loomba, R. S., Younossi, Z. M., Neuschwander‐Tetri, B. A., & Sanyal, A. J. (2020) · Hepatology · doi:10.1002/hep.31599 · Cited by 153
Self-citationHuman Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071629 · Cited by 152
Mak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.040 · Cited by 152
Grimaudo, S., Pipitone, R. M., Pennisi, G., Celsa, C., Cammà, C., Marco, V. D., Barcellona, M. R., Boemi, R., Enea, M., Giannetti, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.011 · Cited by 152
Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH
Loomba, R. S., Neuschwander‐Tetri, B. A., Sanyal, A. J., Chalasani, N., Diehl, A. M., Terrault, N. A., Kowdley, K. V., Dasarathy, S., Kleiner, D. E., Behling, C. A., et al. (2020) · Hepatology · doi:10.1002/hep.31121 · Cited by 151
Self-citationFibrosis imaging: Current concepts and future directions
Baues, M., Dasgupta, A., Ehling, J., Prakash, J., Boor, P., Tacke, F., Kiessling, F. M., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.013 · Cited by 155
He, Y., Hwang, S., Cai, Y., Kim, S., Xu, M., Yang, D., Guillot, A., Feng, D., Seo, W., Hou, X., et al. (2019) · Hepatology · doi:10.1002/hep.30645 · Cited by 151
Simon, T. G., Roelstraete, B., Hartjes, K. T., Shah, U. S., Khalili, H., Arnell, H., & Ludvigsson, J. F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.034 · Cited by 151
Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.041 · Cited by 148
Harrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 148
Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study
Jung, H. S., Chang, Y., Kwon, M., Sung, E., Yun, K. E., Cho, Y. K., Shin, H. C., & Ryu, S. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0283-5 · Cited by 144
Kannt, A., Wohlfart, P., Madsen, A. N., Veidal, S. S., Feigh, M., & Schmoll, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15427 · Cited by 140
Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13688 · Cited by 148
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Ekstedt, M., Nasr, P., & Kechagias, S. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0378-2 · Cited by 141
Self-citationNonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
Alswat, K., Aljumah, A. A., Sanai, F. M., Abaalkhail, F. A., Alghamdi, M., Hamoudi, W. A., Khathlan, A. A., Quraishi, H. A., Rifai, A. A., Zaabi, M. A., et al. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_122_18 · Cited by 141
Cirrhosis as new indication for statins
Bosch, J., Gracia‐Sancho, J., & Abraldeṣ, J. G. (2020) · Gut · doi:10.1136/gutjnl-2019-318237 · Cited by 144
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140
Lee, C.-H., Fu, Y., Yang, S., & Chi, C. (2020) · Nutrients · doi:10.3390/nu12092769 · Cited by 148
Karim, G., & Bansal, M. B. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.60 · Cited by 145
Ajmera, V. H., Kim, B. K., Yang, K. Y., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., Gümüşsoy, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.073 · Cited by 141
Self-citationApplication of transient elastography in nonalcoholic fatty liver disease
Zhang, X., Wong, G. L., & Wong, V. W. (2019) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0001n · Cited by 138
Self-citationFurlan, A., TUBLIN, M. E., Yu, L., Chopra, K. B., Lippello, A., & Behari, J. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21267 · Cited by 138
Lee, D. H., Cho, E. J., Bae, J. S., Lee, J. Y., Yu, S. J., Kim, H., Lee, K. B., Han, J. K., & Choi, B. I. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.034 · Cited by 138
Hardy, T., Wonders, K., Younes, R., Aithal, G. P., Aller, R., Allison, M., Bédossa, P., Betsou, F., Boursier, J., Brosnan, M. J., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106175 · Cited by 141
Self-citationSmirnova, E., Muthiah, M. D., Narayan, N., Siddiqui, M. S., Puri, P., Luketic, V. A., Contos, M. J., Idowu, M. O., Chuang, J.-C., Billin, A. N., et al. (2022) · Hepatology · doi:10.1002/hep.32568 · Cited by 138
Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137
Self-citationKim, D., Konyn, P., Cholankeril, G. T., & Ahmed, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.029 · Cited by 133
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
Sanyal, A. J., Shankar, S. S., Yates, K. P., Bolognese, J. A., Daly, E., Dehn, C. A., Neuschwander‐Tetri, B. A., Kowdley, K. V., Vuppalanchi, R., Behling, C. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02539-6 · Cited by 141
Self-citationHagström, H., Nasr, P., Ekstedt, M., Stål, P., Hultcrantz, R., & Kechagias, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.030 · Cited by 132
Self-citationHarrison, S. A., Bashir, M. R., Lee, K.-J., Shim-Lopez, J., Lee, J. W. J., Wagner, B. L., Smith, N. D., Chen, H. C., & Lawitz, E. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.047 · Cited by 132
Therapeutic management of metabolic dysfunction associated steatotic liver disease
Zeng, J., Fan, J., & Francque, S. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12525 · Cited by 142
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Tincopa, M. A., Anstee, Q. M., & Loomba, R. S. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.011 · Cited by 135
Self-citationTamaki, N., Munaganuru, N., Jung, J., Yonan, A. Q., Loomba, R. R., Bettencourt, R., Ajmera, V., Valasek, M. A., Behling, C., Sirlin, C. B., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324264 · Cited by 130
Self-citationNon-alcoholic fatty liver disease and the interface between primary and secondary care
Tsochatzis, E. A., & Newsome, P. N. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30077-3 · Cited by 130
Liu, F., Goh, G. B., TINIAKOS, D. G., Wee, A., Leow, W. Q., Zhao, J., Rao, H., Wang, X., Wang, Q., Wan, W., et al. (2019) · Hepatology · doi:10.1002/hep.30986 · Cited by 130
Anstee, Q. M., Neuschwander‐Tetri, B. A., Wong, V. W., Abdelmalek, M. F., Younossi, Z. M., Yuan, J., Pecoraro, M. L., Seyedkazemi, S., Fischer, L., Bédossa, P., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105922 · Cited by 132
Self-citationNonalcoholic fatty liver disease burden: Australia, 2019–2030
Adams, L. A., Roberts, S. K., Strasser, S. I., Mahady, S. E., Powell, E. E., Estes, C., Razavi, H. A., & George, J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15009 · Cited by 130
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
O’Hara, J., Finnegan, A. P., Dhillon, H. S., Ruiz‐Casas, L., Pedra, G., Franks, B., Morgan, G., Hebditch, V., Jönsson, B., Mabhala, M. A., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100142 · Cited by 134
Emdin, C. A., Haas, M., Ajmera, V. H., Simon, T. G., Homburger, J. R., Neben, C. L., Jiang, L., Wei, W., Feng, Q., Zhou, A. Y., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.011 · Cited by 131
Self-citationTakeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 131
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126
Metadata
- Authors
- Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., Stal, P., Wong, V. W., Kechagias, S., Hultcrantz, R., & Loomba, R.
- Affiliations
- University of California San Diego (US)
- Mayo Clinic (US)
- Inova Fairfax Hospital (US)
- McGill University Health Centre (CA)
- Linköping University (SE)
- Department of Gastroenterology and Hepatology,Karolinska University Hospital, Karolinska Institutet,Stockholm,Sweden
- Karolinska University Hospital (SE)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Loomba, Rohit
- ORCID
- Venue
- Hepatology
- Published
- 2017-03-31
- Volume
- 65
- Issue
- 5
- Pages
- 1557-1565
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC5397356
- OpenAlex
- W2580009538
- Cited by
- 1,965
- References
- 23
- Citations by year
- 2026: 199 · 2025: 193 · 2024: 227 · 2023: 263 · 2022: 240 · 2021: 272 · 2020: 249 · 2019: 163 · 2018: 101 · 2017: 48
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- American Gastroenterological Association (R01‐DK106419, K23DK090303, 5T32DK007202)
- National Institutes of Health
- Fonds de Recherche du Québec - Santé
- National Institute of Diabetes and Digestive and Kidney Diseases (DK090303, R01DK106419, T32DK007202, K23DK090303)
- National Institute of Environmental Health Sciences (P42ES010337)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, fibrosis stage, mortality risk, all-cause mortality, liver-related mortality, NAFLD progression, simple steatosis, nonalcoholic steatohepatitis, comorbidities, mortality prediction model, liver cancer, liver cirrhosis
- MeSH terms
- Fibrosis, Humans, Liver, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
